Patrick Daly

DocwireNews

Pirtobrutinib, a highly selective, noncovalent Bruton&rsquo;s tyrosine kinase (BTK) inhibitor, was shown to be effective in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were resistant to covalent BTK inhibitors. Researchers evaluated genomic mechanisms of pirtobrutinib resistance in patients with CLL or SLL who had previously received covalent BTK inhibitors, noting that causes of pirtobrutinib resistance had not been systematically investigated.According to their report, presented at the <a href="https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/" target="_blank" rel="noopener">European Hematology Association 2023 Hybrid Congress</a>, patients who progressed on pirtobrutinib commonly showed clearance of BTK C481 clones as well as new or increased non-C481 clones, especially gatekeeper T474 and kinase-impaired L528W mutations, among other variants of unknown significance (VUS).Researchers also observed many acquired BTK mutations were present at baseline with low variant allele frequency (VAF), suggesting they occurred during prior covalent BTK inhibitor therapy. Notably, these mutations did not predict pirtobrutinib resistance. In fact, approximately half of patients who progressed on pirtobrutinib did not acquire BTK mutations, and 29% did not acquire any mutations, indicating alternative mechanisms of resistance.<h3>Genetic Mutations in CLL Don&rsquo;t Predict Response</h3>The analysis included 49 patients with CLL and previous covalent BTK inhibitor treatment who received pirtobrutinib monotherapy in the phase 1/2 BRUIN trial and subsequently experienced disease progression. Targeted next-generation sequencing (NGS) was performed on peripheral blood mononuclear cells collected at enrollment and at or near progression.The cohort had a median age of 69 years (range, 36-86 years), a median of 4 prior lines of therapy (range, 1-10 lines), and 41 (84%) patients had discontinued covalent BTK inhibitors due to disease progression. The overall response rate for pirtobrutinib was 80%The most common baseline mutations were in BTK (51%), TP53 (49%), ATM (27%), NOTCH1 (20%), SF3B1 (18%), and PLCG2 (10%). Among 25 patients with 1 or more BTK alterations at baseline, mutations included BTK C481S (n=23), C481R (n=4), C481Y (n=2), C481F (n=1), and T474I (n=1). Researchers noted a decrease or complete clearance of BTK C481 VAF at time of disease progression in 92% of patients (n=22).NGS of samples collected at progression showed 35 of 49 (71%) patients had acquired 1 or more mutations, and 27 of 49 (55%) had acquired 1 or more BTK mutations. Among those 27 patients, researchers identified 36 acquired BTK mutations.The most common acquired BTK mutations at progression were gatekeeper T474I/F/L/Y (17 of 49; 35%), kinase-impaired L528W (9 of 49; 18%), and VUS proximal to the adenosine triphosphate-binding pocket (6 of 49; 12%), including V416L (n=2), A428D (n=2), D539G/H (n=1), and Y545N (n=1). The most common non-BTK mutations were TP53 (7 of 49; 14%) and PLCG2 (4 of 49; 8%).The researchers summarized that pretreated patients with CLL or SLL who experienced disease progression while on pirtobrutinib showed some similar genomic evolutions, but these were unlikely the only underlying mechanisms of pirtobrutinib resistance. &ldquo;Whether similar patterns of resistance would manifest if pirtobrutinib was utilized in earlier lines of therapy or prior to [covalent BTK inhibitor] treatment remains uncertain,&rdquo; they closed.View More <a href="https://docwirenews.com/category/eha-2023">Highlights from the EHA 2023 Hybrid Congress</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Exploring Genetic Mechanisms of Pirtobrutinib Resistance

EHA 2023

Patients with CLL who progressed on pirtobrutinib shared some common genetic alterations, among other features, but none clearly predicted resistance to treatment.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe